Introducing the Carmine Therapeutics Team

XQ Lin

Board Member, Founding CEO

XQ is the Founder and Managing Partner of EVX Ventures, the corporate venture and incubation arm of Esco Lifesciences Group. He is a seasoned global synergistic business partner to entrepreneurial scientists/innovators.

Tenzin Gocha, Ph.D.

Director, Scientific & Business Operations

Tenzin is an Associate at EVX Ventures and a founding member of Carmine Therapeutics. He obtained his Ph.D. in Molecular Pharmacology from New York University Medical Center.

Jianzhu Chen, Ph.D.

Scientific Advisor

Jianzhu Chen is a Professor of Biology at the Koch Institute for Integrative Cancer Research and at the Massachusetts Institute of Technology Department of Biology.

Ronne Yeo, Ph.D.

Vice President, Discovery

Ronne explores innovative science and platform technologies to build biotech companies that would advance medicine and impact human health. He obtained his Ph.D. in Biological Sciences from the National University of Singapore.

Elan Ezickson

Board Member

Elan Ezickson joined the board in 2019. He brings his extensive strategic, biopharmaceutical, operational, and capital formation expertise to Carmine Therapeutics.

Mark A. Kay M.D., Ph.D.

Scientific Advisor

Dr. Mark Kay is an acknowledged leader in the field of gene therapy and is a leading researcher in both viral and non-viral gene transfer vector systems.

John Robblee, Ph.D.

Vice President, CMC

Dr. Robblee brings over 15 years of development experience to the Chemistry, Manufacturing and Controls (CMC) function at Carmine. He received his Ph.D. from the University of California, Berkeley in biophysical chemistry.

Hon-Ren Huang, Ph.D.

Senior Director of Biology

Dr. Huang received his Ph.D. from the University of Texas Southwestern Medical Center. He completed his post-doctoral training in the laboratory of Prof. Tom Maniatis at Harvard University.